Third Rock Ventures led a $101m Series A in Trace Neuroscience.

Third Rock Ventures, a venture capital firm, led a $101m Series A in Trace Neuroscience, a biopharmaceutical company, with participation from Atlas Venture, GV and RA Capital Management. “UNC13A is a highly compelling genetic target directly linked to ALS disease progression and survival. Insights from the human genome have led to transformative medicines for many diseases, and with what we now know about the role of UNC13A, we believe the time is right to apply this approach to ALS. We envision a world where UNC13A restoration improves outcomes across a range of neurodegenerative diseases, including for the approximately 30,000 people in the U.S. living with ALS,” Eric Green, M.D., Ph.D., Trace Neuroscience Co-Founder and CEO.